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South Africa is unique in the arena of Intersex, in that for unknown reasons we have a very high 
percentage of ovotesticular DSD (True Hermaphrodite). Whereas ovotesticular DSD is the 
least common cause of hermaphroditism in other parts of the world, it is the most common cause 
of hermaphroditism in South Africa.  There have been several studies in the past to determine the 
cause of ovotesticular DSD in our population but none of these studies found appropriate 
answers.  
The current state of understanding implicates signaling and signal transduction molecules and 
transcription factors suggesting that it is likely not all of the genetic factors involved have 
already been identified. 
It was hypothesized that exome sequencing of individuals with DGDs will identify new 
mutations and genes for these conditions.  
Therefore, this study aims to identify additional genes that are associated with ovotesticular 
DSD. By using a whole-genome sequencing approach we expected to be able to identify rare 
variants with this condition and determine the prevalence of mutations in these genes in the 
ovotesticular DSD population. 
After obtaining informed consent, blood specimen was obtained from eleven out of fifteen 
patients who had histological diagnosis of Ovotesticular DSD at the Red Cross War Memorial 
Hospital over a 10 year period. Blood specimen was also obtained from the biological parents of 
these children and sent to the Ostrer laboratory for whole genome sequencing and analysis. 
At the Ostrer laboratory, high quality DNA was extracted from blood for all of subjects and 
lymphoblastoid cell lines were created. Following sample preparation using the Illumina library 
preparation kit, sequencing was accomplished using paired-end sequencing technology on an 
Illumina HiSeq2000 sequencer. The data from the Illumina sequencers was analyzed first using 
the Illumina sequencing data analysis pipeline for quality control. 
Paired end reads were aligned to the Human Reference Genome (NCBI Build 36) using the 
BWA software. Each alignment was assigned a mapping quality score by BWA, which is the 
Phredscaled probability that a read is misaligned. The basic functional annotation of SNPs/Indels 
is performed by ANNOVAR.  
The clinical features of these patients was consistent with those found by other studies on 
Ovotesticular DSD in South Africa and it also showed the same pattern of variation to the 
clinical features of Ovotesticular DSD from other parts of the world. 
xi 
 
Similar to previous South African studies, this study found no convincing gene mutations as the 
possible etiology of Ovotesticular DSD in South Africa. 
Whiles gene mutations such as duplication of SOX 9 have been found in patients with XX 
Ovotesticular DSD from outside South Africa, this study could not identify any such mutations. 
This further adds to the suspicion that the unique features of Ovotesticular DSD in South Africa 
suggests a different etiology from that of other parts of the world. 
In conclusion, the etiology of Ovotesticular DSD in South Africa still remains elusive. It is 
however possible that a genetic mutation may be found from a more critical analysis of the 
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      1.1 Rationale for the Study 
Disorders of sexual development (DSDs) affect 1 in 10,000 individuals in the population or 
10,000 individuals between birth and age 25 in the United States.(1–3) Among these are 
46XX testicular DSD (formerly called “XX maleness”), 46XY DSD with partial or complete 
gonadal dysgenesis, and 46XX ovotesticular DSD (formerly called “true hermaphroditism”). 
The term “Disorders of sexual development (DSDs)” was selected to differentiate these 
subjects from others with disorders of sexual development (DSDs) that arise from hormone 
biosynthetic defects or androgen insensitivity. 
 
These disorders are identified at different times in the life course.(4) They may be recognized 
at birth due to ambiguous genitalia, or may not be diagnosed until later in life, when puberty 
is delayed, or there is unanticipated virilization or gynecomastia. While most individuals with 
DSD s do not suffer from cognitive or general health impairments, the diagnosis of a DSD 
can have substantial effects on the affected and their families. Depending upon when the 
DSD is diagnosed, parents may have to make difficult decisions regarding sex assignment 
and the affected may be assigned a gender of rearing that is discordant for their sex 
chromosome constitution, possibly resulting in a reassignment. This can lead to gender 
dysphoria later in life and may result in the affected requiring gender-corrective surgery 
and/or hormonal therapies. Moreover, the affected may not be the only affected member in 
the family. Diagnosis of DSD s relies upon multiple sources of information, including 
clinical findings, gonadal histology, chromosome analysis, and genetic testing of known 
associated mutations (discussed below). These conditions may be sporadic or inherited in an 
autosomal dominant, autosomal recessive, X-linked, or Y-linked manner. 
 
South Africa is unique in the arena of Intersex, in that for unknown reasons we have a very 
high percentage of ovotesticular DSD (True Hermaphrodite). Whereas ovotesticular DSD 
is the least common cause of hermaphroditism in other parts of the world, it is the most 
common cause of hermaphroditism in South Africa.  There have been several studies in the 
past to determine the cause of ovotesticular DSD in our population but none of these studies 
found appropriate answers.(5,6) These studies looked extensively for environmental, familial 
and even genetic factors but the cause of ovotesticular DSD in South Africa still remains 
elusive. 
The current state of understanding implicates signaling and signal transduction molecules 
and transcription factors suggesting that it is likely not all of the genetic factors involved 
have already been identified. 
Therefore, this study aims to identify additional genes that are associated with ovotesticular 
DSD. By using a whole-genome sequencing approach we will be able to identify rare 
variants, including structural variants that are associated with this condition and determine 








Genetic Correlates of DGD 
 
Many of the sex-determining genes were identified by studying cases of DSDs. Table 1 provides 
a summary of genes that have shown association with one or more of the DSD.(1–3),(7–19) 
 
 
Table 1. 1: Known gonad determining genes based on mutations resulting in abnormal 
gonadal development 
 




ATRX Alpha-thalassemia/mental retardation/hypotonic 
facies 
Xq21.1 300032 
DHH  12q13.12 605423 
MAP3K1  5q11.2 600982 
NR5A1 (SF1) Adrenocortical insufficiency 9q33.3 184757 
NR0B1 
(DAX1) 
 Xp21.3-p21.2 300473 
RSPO1 Palmoplantar hyperkeratosis, squamous cell 
carcinoma 
1p34.3 609595 
TSPYL1 Sudden infant death 6q22-q23 604714 
WNT4 Dysgenesis of kidneys, adrenals and lung 1p35 603490 
WT1 Nephropathy, Wilms tumor 11p13 607102 
SOX9 Campomelic/acampomelic dysplasia 17q24.3-q25.1 608160 
SRY  Yp11.3 480000 
 
Although the genes listed in Table 1.1 can explain some cases of DSD s, they cannot account for 
them all. The prevalence of patients with mutations in these genes that could explain their 
condition is thought to be 25% overall; although other factors, such as epigenetic effects, may 
explain some of the remaining cases, it is unlikely that all of the genetic factors have already 
been identified.  Therefore, the proposed study aims to identify additional genes that are 
associated with DSDs. By using a whole-genome sequencing approach we will be able to 
identify rare variants, including structural variants that are associated with these conditions. 





Exome sequencing of individuals with DSD s will identify new mutations and genes for these 








1. To define the genes and causal variants in unique families with multiple cases of DSD s where 
the genes are unknown employing whole exome sequencing. 
 










































                                                          CHAPTER TWO 
 
2.0. INTRODUCTION 
2.1. Disorder of Sexual Differentiation 
Diverse disorders of sexual development exist have been recognized in man since ancient times. 
The question of what determines whether an organism shall develop into a male or a female has 
been debated long before science developed. There are many ancient myths of a hermaphrodite 
origin of man and his subsequent bisection into male and female individuals. According to some 
rabbinical tradition, Adam and Eve were originally a hermaphrodite being, who was 
subsequently bisected. Many ancient philosophers, such as Heroditus and Plato, make reference 
to hermaphrodite beings in their writings.(20) 
The term “Hermaphrodite” is derived from the son of Hermes and Aphrodite, called 
Hermaphroditus, who according to Greek mythology united with the nymph of the Fountain of 
Salmacis, a female, the two becoming one person and possessing both male and female sexual 
characteristics. 
The idea of males and females originating from hermaphrodite origins agrees well with the 
embryological evidence. The primitive genital ridge is bipotential, containing components that 
can form either a testis or an ovary, while two sets of genital ducts, the Mullerian and 
Mesonephric ducts are the beginnings of the female and male internal genitalia respectively. 
It is now know that DSDs arise from errors in sexual development of the early embryo which has 
the potential to develop as either a male or a female. This results in abnormalities in the gonads 
and/or other internal organs and/or external genitalia. They were previously referred to as 
hermaphrodites or intersex however; recent advances in molecular biology and genetic research 
have provided new insight into the precise mechanisms responsible for sexual differentiation and 
for specific disorders of sexual development. Hence, the nomenclature has improved in order to 
promote precise communication among colleagues and respect for the sensitivity of patients by 
eliminating terms such as pseudohermaphroditism, which have been regarded as pejorative by 
patients. The term intersex disorders have been replaced by disorders of sex development 
(DSDs). It is now known that Sexuality has many aspects to it: chromosomal, gonadal, 
hormonal, phenotypic, psychological or assumed gender role and sexual orientation. All these 
components of sexuality are considered in a holistic approach to managing DSDs and not just the 
phenotypic appearance alone. 
The incidence of DSD individuals worldwide is relatively low and the most common DSD 
anomaly reported in the world is that of 46XX DSD (masculinized female) from Congenital 
Adrenal Hyperplasia with the Ovotesticular DSD (true hermaphrodite) being the least common 
variants. However, in his report, van Niekerk’s found that Ovotesticular DSD is the most 
common DSD in South Africa, occurring among the Bantu-speaking people.(20) 
True hermaphrodites/ Ovotesticular DSD individuals have both ovarian and testicular tissue. The 
two tissues may be present in either the same gonad, an ovotestis, or as separate gonads (an 






2.1.1 Ovotesticular DSD 
Salen described the first true hermaphrodite in the literature in 1899 however; Klebs is usually 
credited with the first scientific consideration of Ovotesticular DSD. (5)  By the beginning of the 
modern cytogenetic era (circa 1958), approximately 200 Ovotesticular DSD had been 
documented. The diagnosis needs to be confirmed histologically, and gonadal biopsies are 
therefore a necessary part of the investigations. The pathognomonic histologic feature of true 
hermaphroditism is the presence of seminiferous tubules and ovarian follicles or oocytes, 
representing testicular and ovarian tissue, both seen in the same patient. The single commonest 
gonad seen in such patients is the ovotestis, which combines these 2 sex-opposite tissues in a 
single gonad. (20) 
The most frequent karyotype in these patients is 46, XX or various forms of mosaicism, whereas 
46XY is very rarely found. (21,22) 
. 
2.1.2. Classification of Ovotesticular DSDs 
Four (4) methods have been used to classify true hermaphrodites. These 
Methods are based on the histopathologic findings of the gonads found. 
i. Klebs Classification (1876) 
This method for classifying true hermaphrodites was found to be impracticable, complex and 
incomplete. It is, therefore, no longer used. 
 
ii. Hinman Classification (1935) 
Most authors use this classification which is in three groups: 
a. Group I, bilateral 
An individual who has an ovary and a testis, either separate or united as an ovotestis, on both 
sides. 
b. Group II, unilateral 
Any person having a testis and an ovary, either separate or united as an ovotestis, on one side, 
and either a testis or an ovary on the opposite side. 
c. Group 1I1, lateral 
Any individual with a testis on one side and an ovary on the opposite side. 
iii. Jones and Scott Classification (1958) 
This method of classification is essentially identical to the Hinman classification. 
The only difference is the subdivision of the three varieties into groups. 
 
Table 2.1 Jones and Scott classification 
 









































iv. Sasaki and Makino Classification (1960) 
Although this method lists the different combinations of gonads, they are not grouped into the 
three main categories, namely: lateral, bilateral and unilateral. Hence, it is not commonly used. 
 
Table 2.2 Sasaki and Makino classification 
 
GROUP GONAD ONE SIDE GONAD OPPOSITE SIDE 
 
Group 1 Ovary Testis 
 
Group 2 Ovotestis Ovotestis 
Group 3 Ovary Ovotestis 
Group 4 Testis Ovotestis 
Group 5 Ovotestis No gonad 
 




2.1.3. Clinical features of Ovotesticular DSD 
 
2.1.3.1 Presenting symptoms 
The external genitalia and internal duct structures of ovotesticular DSD display gradations 
between male and female. In most patients the external genitalia are ambiguous but masculinized 
to variable degrees, and 75% are raised as male. Among those raised as male, hypospadias and 
chordee occur in approximately 80%. Among those patients raised as females, two thirds have 
clitoromegaly. Virtually all patients have a urogenital sinus, and in most cases a uterus is present. 
The ovary is found in a normal location, more commonly on the left side. The testis or ovotestis 
may reside at any point along the path of testicular descent. Testes and ovotestes are more 
commonly located on the right side(23). Sixty percent of gonads palpable in the inguinal canal or 
labioscrotal folds are ovotestes, which may be clinically suspected on the basis of a difference in 






2.1.3.2. The types of gonads 
The three types of gonads that can be found in true hermaphrodites’ are an ovary, testis and 
ovotestis. 
i. The ovotestis 
The ovotestis is one of the most unique features of Ovotesticular DSD. 
The location of the ovotestis, i.e., in the ovarian or scrotal position, seems to be influenced by the 
proportion of ovarian to testicular tissue in it. The greater the mass of testicular tissue present, 
the greater the chances that the ovotestis will descend from the ovarian position to the inguinal or 
scrotal region(20). 
Macroscopically, ovotestes can be bilobed or ovoid. If bilobed, testicular and ovarian tissues 
are joined by a pedicle. If ovoid, the ovarian tissue forms a cap on the testicular parenchyma. The 
limits between testicular and ovarian parenchyma may be well defined in some cases, while in 
others the oocytes are spread among seminiferous cords/tubules, or even inside the tubules. The 
ovarian/testicular proportion of tissue varies widely from one patient to another. The testicular 
zone neighboring the ovarian component shows significant changes in interstitium and tunica 
albuginea. The interstitial tissue has ovarian-like stroma, not the characteristic loose connective 
tissue of a normal testis. The tunica albuginea covering the testicular zone shows poor 
differentiation with persistence of tubular structures within it or that cross it to reach the 
mesothelial surface. The mesothelial lining of this zone can be columnar instead of flattened. 
 
ii. The ovary 
In the majority of cases the histological features of the ovarian tissue was described as well 
developed and essentially normal, even when it was part of an ovotestis. Most ovaries found in 
Ovotesticular DSDs do show signs of ovulation. (25). This is substantiated by reports in the 
literature of Ovotesticular DSD females giving birth to normal children with normal appearing 
external genitalia(26–28). 
 
iii. The testis 
In contrast, the testicular tissue, from the testis and ovotestis, of Ovotesticular DSD patients is 
immature with interstitial fibrosis and no, or rare, spermatogonia (29). Spermatogenesis is rarely 
found and occurs in a separate testis. There is a rare report of a male patient with 
46XX/46XYOvotesticular DSD fathering a child. (30). 
 
2.1.3.3 The distribution of gonads 
 
When the gonadal distribution was looked at in 694 Ovotesticular DSDs (data collected 
from six papers), the unilateral Ovotesticular DSD with an ovary on one side and an ovotestis on 
the opposite side was present in 33.0% of the cases cited in the literature. 
The bilateral (ovotestis on both sides of the body) and lateral (an ovary on one side and 








Table 2.3: Gonadal distribution in 694 true hermaphrodites(20–22,25,29,30)(van Niekerk, 1974 
[n=24];van Niekerk, 1976 [n=3]; van Niekerk& Retief, 1981b [n=382]; Ramsay et al, 
1988[n~37]; Hadjiathanasiou et al, 1994 [n=22j; Krob et al, 1994 [n=226j) 
 
TYPE OF DISTRIBUTION NUMBER OF PATIENTS PERCENTAGE (%) 
Ovary-Testis 169 24.35 
Ovotestis-Ovary 229 33.00 
Ovotestis-Ovotestis 176 25.36 
Ovotestis-Testis 78 11.24 
Ovotestis-? 19 2.74 
Others 23 3.31 
 
 
From the above data (Table 2.3), the cases of Ovotesticular DSD reported in the South African 
black population, a very different distribution frequency of the gonads would be observed. The 
27 patients of van Niekerk(20,31) together with the 37 cases of Ramsay et al,(22) showed that 
the unilateral (ovotestis - ovary/testis) Ovotesticular DSD accounted for 62.50% of the cases. 
The second most frequent gonadal distribution was that of the bilateral ovotestis 
(17.19%). The differences observed for the gonadal distribution are statistically significant at the 
5% level (p = 0.0196). This may imply a different cause of hermaphroditism in the South African 
black population. Vilain stated that the distribution worldwide is 34% ovotestes/ovary, 29% 
ovotestes/ovotestes and 25% ovary/testes(32) 
Of the 694 true hermaphrodites examined in Table 2.3, the location of the gonad on either the 
left or right hand side of the body is given for 1363 of the gonads. This information is presented 
in Table 2.4 
A study by Wiesmar and Ramdial in South Africa in 2008 showed the composition of the 
ovotestis. The ovotestes were divisible on gross appearance into 11% bipolar and 89% mixed 
types. Histologically, the mixed-type ovotestes have an outer mantle consisting of ovarian tissue, 
which encapsulated an inner core of 2 distinct types. The first is an admixed ovotestis 
(constituting 44% of the mixed ovotestes), the central core consisted of gonadal stroma, with 
scattered foci of separate ovarian and testicular tissue. The second type was the 
compartmentalized ovotestis (constituting 56% of the mixed ovotestes); here, the outer mantle 
was thickened in the upper pole and encapsulated a large core of testicular tissue in the lower 
pole of the gonad. The bipolar ovotestis had a strictly polar distribution of ovarian and testicular 
tissue, which had an irregularly interdigitating junction between the 2 types of tissue.(33) 
 
Table 2.4: The incidence of gonads occurring on the left or right side in true 
Hermaphrodites 
GONAD LEFT (%) RIGHT (%) TOTAL NUMBER 
OBSERVED (%) 
Ovary 288 (43.11%) 135 (19.42%) 423 (31.03%) 
Testis 105 (15.72%) 159 (22.88%) 264 (19.37%) 
Ovotestis 275(41.17%) 401 (57.70%) 676 (49.60%) 
9 
From the data above it is seen that the ovary is more prevalent on the left side, while the testis 
and ovotestis occur more frequently on the right side of the body. It is also noted that the 
ovotestis is the most common gonad in the Ovotesticular DSD accounting for 49.60% of the 
gonads. The second most common gonad is the ovary (31.03%) and the least common is the 
testis (19.37%). 
The asymmetry in the position of ovaries and testes in patients with Ovotesticular DSD is not 
easily explained in genetic terms, since a testis-determining gene product would be expected to 
be present in equal quantities on both sides.  However, if gonadal differentiation ultimately 
depends on rates of growth, the question arises whether the asymmetry of gonadal growth in 
hermaphroditism can be related to an underlying asymmetry of the human body. This possibility 
can be measured by comparing growth characteristics in right and left gonads of normal human 
fetuses(34,35). The average differences between left and right gonads (calculated by subtracting 
values of left gonads from those on the right and expressing the difference as a percentage of the 
mean for each fetus) were studied. It was found that, on average, right gonads exceed left gonads 
in the three variables investigated, i.e. weight, protein and DNA contents, and hence in numbers 
of cells. The mean differences are between 6 and 7 % for testes and about 13 % for ovaries. 
Since testes exceed ovaries in the same criteria used for assessing growth, the relationship 
between growth and differentiation in human gonads could be determined. Ovaries are smaller 
and grow less fast than testes; left gonads are smaller and grow less fast than right gonads. If 
there were any causal relationship between these phenomena, we would expect left gonads to 
have a tendency to become ovaries and right gonads to differentiate into testes. In normal 
development this relationship is of no consequence, since the sex-chromosome constitution will 
override all other tendencies. However, in Ovotesticular DSD, we witness the breakdown of the 
sex-chromosomal mechanism, and we also see the bilaterally asymmetrical development of 
ovaries and testes in accordance with the basic asymmetry of normal gonadal development. 
2.1.3.4 Distribution of karyotype 
There are three different karyotypes found in patients with ovotesticular DSD; 46XX, 46XY and 
mosaics with 46XX/XY. The most common is the 46XX ovotesticular DSD as was found by van 
Niekerk et al upon examination of 195 confirmed ovotesticular DSD(20).  46,XX was the most 
common karyotype, occurring in 59,5% of the cases; 12.8% of the ovotesticular DSD patients 
had a 46,XX/46,XY mosaic pattern while the 46,XYkaryotype was found in 12.3% of the 
patients analyzed. The remaining 15.3% of cases showed different mosaic cell lines(21). 
46,XX/46,XY Ovotesticular DSD could result from: (1) fertilization of both an ovum and its 
polar body; (2) fertilization of each of two ova contained within a single binucleated follicle; (3) 
fertilization of ova derived from different follicles, followed by fusion; or (4) other related 
phenomena. The etiology of 46XX/46XY Ovotesticular DSD in humans is usually considered to 
be chimerism, rather than nondisjunction. After  reviewing 283 cases of human ovotesticular 
DSD published from1980 to 1992, Krob et al found the 46,XX karyotype to occur in 70.6% of 
cases(30).Chromosomal mosaicism (20.2%) was the second most common group and the 
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46,XYkaryotype accounted for 7% of cases. It is interesting to note that in South Africa, 87 of 
the 88 patients of black or mixed black origin on whom karyotyping was performed had a 
46,XXchromosome complement (21,22). In cases reported from other regions, as summarized by 
Krob et al, 1994, only 52% of the hermaphrodites had a 46,XX karyotype(30).  This and the fact 
that the distribution of gonads differs to that in the rest of the world may be an indication that the 
aetiology of Ovotesticular DSD in the South African black population is different to that from 
other parts of the world. 
It is important to note from these data that among those with 46XX Ovotesticular DSD, the 
gonadal distribution was mostly unilateral (37%), i.e., an ovary on one side and an ovotestis on 
the opposite side of the body. The second most common gonadal distribution 46,XX 
Ovotesticular DSD was a bilateral ovotestis in 28.4% of the cases followed by the lateral gonadal 
distribution.(25) 
 
2.1.3.5 External genitalia 
The development of male type external genitalia is believed to be an effect of 
dihydrotestosterone. The testicular tissue in the Ovotesticular DSD seems to be capable of 
differentiating the ipsilateral Wolffian duct, but incapable of fully differentiating male type 
external genitalia. However, despite this, the sex of rearing of 126 case reports of Ovotesticular 
DSD in the literature were 73% reared as male and 27% as female. 
This may probably be because most Ovotesticular DSD patients have a clitorophallus, measuring 
between two to eight centimeters long at birth(25). 
Absence of either clitoral enlargement or a phallus in Ovotesticular DSD is an exception to the 
rule. The vast majority of patients have one or the other (20). 
Overzier classified various abnormal external genitalia found in DSD cases as Types 
I, II, III, IV, and V. Type I corresponds to normal female external genitalia whiles in Type II, a 
common external orifice is present. In Type III, a urogenital sinus is located interior to the 
clitoris or phallus. Type IV shows an internal urogenital sinus and Type V shows normal male 
external genitalia. External genitalia of the majority of Ovotesticular DSD 
reported in the literature were Types III and IV (20). 
2.1.4 Diagnosis 
The possibility of Ovotesticular DSD should be considered whenever a patient with ambiguous 
genitalia is being examined. Palpating the gonad which may be present in one of the labioscrotal 
folds is important(20). In Ovotesticular DSD, the gonad is usually present in the right 
labioscrotal fold or in the right hemiscrotum. It is also important to palpate carefully for any 
difference in consistency especially at the polar ends of the gonad. In an ovotestis, the testicular 
portion feels firm whiles the ovarian portion is quite soft.  Cytogenetic studies and hormonal 
evaluations should be performed. Laparoscopy is done to visualize the internal genitalia and look 
for gonads which are biopsied for histopathology. Usually, Wolffian structures are found 
Ipsilateral to a testis and a fallopian tube seen Ipsilateral to an ovary. Either a fallopian tube or 
ovary is seen Ipsilateral to an ovotestis although usually it is a fallopian tube that is seen. A 
normal or rudimentary uterus may also be seen at laparoscopy. It is unusual to find both fallopian 
tube and Wolffian structures Ipsilateral to an ovotestis but this has been reported(36). 
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The diagnosis of a Ovotesticular DSD is confirmed once ovarian and testicular tissues have been 
histologically demonstrated on gonadal biopsy.(37) 
 
 
2.1.5 Sex of rearing 
 
Sex assignment is an issue in these patients, and the considerations are similar to those in DSD in 
general (38). In the past, there was a tendency for patients with Ovotesticular DSD to be reared 
as males since most have a phallus at birth. Of 146 Ovotesticular DSD reported in the literature, 
approximately 75% were reared as males(20). Worldwide, two thirds of all Ovotesticular DSD 
patients are raised as males (39). 
The choice of sex assignment for raising the patients was made according to the age of the 
patient at diagnosis, the clinical and hormonal data, the degree of virilization of the external 
genitalia, and the familial and cultural context. 
A particular aspect in sex assignment may derive from the fact that the ovarian tissue may be 
normal enough to produce oocytes. Therefore, female assignment with special attention to the 
preservation of ovarian tissue may be favored in these cases. To date, there are less than 20 cases 
of pregnancy reported in patients with ovotesticular DSD raised as females, and the majority 
have had complications like preterm labor or morbidity related to the delivery process, as a 
consequence of defects in the female reproductive tract(40). 
The decision on sex of rearing in ovotesticular DSD should consider the potential for fertility 
based on gonadal differentiation and genital development, and assuming the genitalia are, or can 




The management of children with Ovotesticular DSD is a multidisciplinary approach including 
teams of specialist geneticists, paediatric endocrinologists, paediatric urologists, counselors and 
the child’s parents. 
 
2.1.6.1 Surgical treatment 
 
In order to treat a hermaphrodite effectively, the first prerequisite is to decide on the gender of 
rearing. Initial gender uncertainty is unsettling and stressful for families. Expediting a thorough 
assessment and decision is required. Factors that influence gender assignment include the 
diagnosis, genital appearance, surgical options, need for life- long replacement therapy, the 
potential for fertility, views of the family, and sometimes the circumstances relating to cultural 
practices. 
 
When necessary, surgical reconstruction can be done. The surgeon has a responsibility to outline 
the surgical sequence and subsequent consequences from infancy to adulthood.  If the child is to 
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be raised as a female, removal of all testicular tissue present and labioscrotal reductions can be 
accomplished in early infancy. Clitoral reduction surgery should only be considered in cases of 
severe virilization (Prader III, IV, and V) and should be carried out in conjunction, when 
appropriate, with repair of the common urogenital sinus. As orgasmic function and erectile 
sensation may be disturbed by clitoral surgery, the surgical procedure should be anatomically 
based to preserve erectile function and the innervation of the clitoris. Emphasis is on functional 
outcome rather than a strictly cosmetic appearance. It is generally felt that surgery that is carried 
out for cosmetic reasons in the first year of life relieves parental distress and improves 
attachment between the child and the parents(41–44).The systematic evidence for this belief is 
lacking. Parents now appear to be less inclined to choose surgery for less severe clitoromegaly, 
which is normally the case in Ovotesticular DSDs being raised as female(45).  Vaginal dilatation 
should not be undertaken before puberty. An absent or inadequate vagina (with rare exceptions) 
requires a vaginoplasty performed in adolescence when the patient is psychologically motivated 
and a full partner in the procedure. 
If patients are to be raised as males, then various types of hypospadias repair can be done, 
gonads can be replaced with prostheses, the prepenile scrotum can be reconstructed, and 
Mullerian structures can be removed with the goal of preserving the vas deferens. There is no 
evidence that prophylactic removal of asymptomatic discordant structures, such as a utriculus or 
mullerian remnants, is required although symptoms in future may indicate surgical removal. In 
the patient assigned a male gender role, care should be taken to identify and remove all ovarian 
tissue. Partial gonadectomy requires a special comment: patients raised as boys, the ovarian 
portion needs to be removed before pubertal age to avoid estrogen elevation resulting in 
gynecomastia and other features of heterosexual pubertal development, and also to prevent 
complications of cystic follicles that may develop in response to elevated FSH. In patients raised 
as females, testicular tissue needs to be removed to avoid virilization during puberty. Generally, 
most ovotestis are excised completely because they may be admixed or because of difficulty with 
precise cleavage of discordant gonadal tissues. Concerning the risk of tumor development in the 
testicular portion, it has been reported to be low even if the tissue is dysgenetic, especially in the 
absence of Y chromosome sequences(46). 
 
2.1.6.2   Sex Steroid Replacement 
 
Most of these patients will require hormone replacement therapy in view of the fact that there is 
removal of the ovotestis early in infancy. The timing of initiation of puberty may vary but this is 
an occasion that provides an opportunity to discuss the condition and set a foundation for long 
term adherence to treatment. Hormonal induction of puberty should attempt to replicate normal 
pubertal maturation to induce secondary sexual characteristics, a pubertal growth spurt, and 
optimal bone mineral accumulation, together with psychosocial support for psychosexual 
maturation(47). Intramuscular depot injections of testosterone esters are commonly used in 
males; other options include oral testosterone undecanoate, and transdermal preparations are also 
available(48–50). Females require estrogen supplementation to induce pubertal changes and 
menses. A progestin is usually added after breakthrough bleeding develops or within one to two 
years of continuous estrogen. There is no evidence that the addition of cyclic progesterone is 




2.1.6.3 Psychosocial management 
 
Psychosocial care provided by mental health staff with expertise in DSD should be an integral 
part of management in order to promote positive adaptation. This expertise can facilitate team 
decisions about gender assignment/reassignment, timing of surgery, and sex hormone 
replacement. Psychosocial screening tools that identify families at risk for maladaptive coping 
with a child’s medical condition are available(51). Once the child is sufficiently developed for a 
psychological assessment of gender identity, such an evaluation must be included in discussions 
about gender reassignment. Gender identity development begins before the age of 3 years, but 
the earliest age at which it can be reliably assessed remains unclear(52). The generalization that 
the age of 18 months is the upper limit of imposed gender reassignment should be treated with 
caution and viewed conservatively. Atypical gender role behavior is more common in children 
with DSD than in the general population but should not be taken as an indicator for gender 
reassignment. In affected children and adolescents who report significant gender dysphoria, a 
comprehensive psychological evaluation and an opportunity to explore feelings about gender 
with a qualified clinician is required over a period of time(53). If the desire to change gender 
persists, the patient’s wish should be supported and may require the input of a specialist skilled 
in the management of gender change. The process of disclosure concerning facts about 
karyotype, gonadal status, and prospects for future fertility is a collaborative ongoing action 
which requires a flexible individual based approach. It should be planned with the parents from 





2.1.7 Prevalence of 46XX Ovotesticular DSD in South Africa 
 
In southern Africa ambiguous genitalia is more common in blacks than in whites. In a study by 
Ramsay et al 152 black and only 31 white patients were referred to their laboratory, over a four 
year period, for chromosome analysis because of ambiguous genitalia(22). All thirty eight of the 
black patients, who were histologically examined, were proven to be Ovotesticular DSD; the 
remaining 114 had an XX karyotype but were not histologically examined. None of the 31 white 
patients was confirmed to be an Ovotesticular DSD on histological examination. The majority of 
white patients were affected with congenital adrenal hyperplasia. 
46XX Ovotesticular DSD is thus, unusually prevalent in southern African blacks. This raises 
concern that there must be some unique factor(s) causing the high incidence of this sexual 
anomaly in blacks and, it seems likely that the condition has a common etiological and 
pathogenetic basis in this population. Ovotesticular DSD is the least common intersexual 
anomaly in the world, however, it is the most common type of intersexuality in the Bantu 
speaking people of South Africa(20). Thus, there seems to be a special predisposition in them 






2.1.7.2. Familial incidence 
In general, Ovotesticular DSD occurs sporadically. However, although not common, the 
occurrence of 46XX Ovotesticular DSD in siblings has been reported in the literature(55).This 
suggests a possible genetic etiological factor for this condition(20). 46,XX males sometimes co-
exist in the same family with Ovotesticular DSD(56,57) 
Four families have so far been reported where 46XX Ovotesticular DSD co-exist with 
46,XX males suggesting that both disorders are variations of the same genetic defect(58).  The 
presence of male sexual development in genetic females, with transmission through normal male 
and female parents, indicates that the critical genetic defect may be a new mutation manifesting 
as an autosomal dominant trait. The different phenotypic manifestations arise from variable 
expressivity(57) or an X-linked mutation (limited by the presence of the Y chromosome)(59). In 
these cases a common origin of the sex determining disorder has to be postulated(30). 
 
2.2. The aetiology of 46XX Ovotesticular DSD 
The genetic mechanism(s) responsible for 46XX Ovotesticular DSD remains elusive. 
Ovotesticular DSD is a genetically heterogeneous condition with several possible 
causes. Three major hypotheses have been proposed to explain the aetiology of Ovotesticular 
DSD and the phenomenon of testicular differentiation that occurs despite the fact that 
approximately 60% of these individuals have an XX karyotype and lack the 
Y chromosome: 
i. Mosaicism with a loss of the Y containing cell line, presumably after it had initiated gonadal 
differentiation into a testis at an early embryonic stage, is the oldest 
explanation proposed(60–62). 
ii. Translocation of chromosomal material encoding the testis determining factor 
(TDF) from the Y chromosome to an autosome or X chromosome during meiotic division is 
another possibility. If this were the correct explanation, a high familial incidence would be 
expected, but few families with XX true hermaphroditism have been described (63). 
iii. An autosomal or X-linked dominant mutation that permits testicular determination 
in the absence of TDF thus allowing XX zygotes to assume a male phenotype(61,62) 
There is no direct evidence that a single gene mutation such as this occurs in humans. 
The unusually high prevalence of 46XX Ovotesticular DSD in southern African blacks suggests 
that the condition has a common cause and pathogenesis in this population. 
A study by Spurdle et al of 16 46XXOvotesticular DSD patients failed to reveal the presence of 
the SRY locus and the pseudoautosomal boundary of the Y chromosome (PABY)(64). 
 
Y chromosome sequences are thus very unlikely to be involved in the cause of the disorder in 
southern African Bantu-speaking blacks. Ramsay et al obtained detailed family histories for 11 
of their 38 46XX Ovotesticular DSD patients. 
They concluded that it is unlikely that mutation of a single gene, either autosomal or sex 






2.2.1. Normal fetal sex determination and gonadal differentiation 
 
The most obvious distinction among humans is that of gender.  In the history of mankind, both 
scientists and non-scientists, have always been fascinated and perplexed by the biological 
processes that determine the sex of an individual(65). 
Sexual dimorphism in humans has been the subject of wonder for centuries. In 355 BC, 
Aristotle postulated that sexual dimorphism arose from differences in the heat of semen 
at the time of copulation. In his scheme, hot semen generated males, whereas cold 
semen made females(66). The Greeks believed it was the level of male excitement during 
intercourse that determined whether the child would be male or female - the more excited the 
man, the grocer the likelihood of siring a boy(67). 
It is now known that sexual differentiation relies on the establishment of chromosomal sex at 
fertilization, followed by the differentiation of the gonads which ultimately guides the 
establishment of phenotypic sex. A cascade of complex molecular and morphological events 
must occur at the appropriate time and in the correct sequence in order for an organism to 
develop into a 'normal' male or female. 
Each event in sexual determination depends on the preceding event, and normally, chromosomal, 
gonadal, and somatic sex all concur. There are, however, instances where they don't agree, and 
sexual differentiation is ambiguous, with male and female characteristics combined in a single 
individual. Analysis of such individuals has permitted identification of some of the genes 
involved in sex determination (66). 
 
 
2.2.2. Chromosomal, gonadal and phenotypic sex 
 
Sexual development in the mammalian embryo involves three sequential processes. 
The first step, which occurs at fertilization, is to establish chromosomal sex (by the content of the 
sex chromosomes). Females will normally be XX and males XY, but the number of X 
chromosomes is irrelevant as the Y behaves as a dominant male determinant. Secondly, the 
indifferent gonads begin to differentiate into either testes or ovaries (gonadal sex). Ovarian 
differentiation can be considered the default pathway, which is 'overridden' in males by the testis 
determining gene, TDF, found on the Y chromosome; and thirdly, the differentiation of internal 
and external genitalia, that is, the translation of gonadal sex into phenotypic sex(68,69). The 
pioneering experiments of Alfred Jost  in  1953established our understanding about the 
determining effect of the gonadal ridge development into a testis for the male differentiation of 
the internal and external genitalia, due to the secretion of testosterone and a second testicular 
factor, subsequently characterized as the anti-Mullerian hormone (AMH)(70). In their absence, 
internal and external genitalia follow the female pathway. The degree of virilization of the 
internal and external genitalia and of the regression of Mullerian ducts depends on the mass of 
functional testicular tissue present in the narrow window of fetal dimorphic sex 
differentiation(71). A few years after Jost’s work, the determining role of the Y chromosome for 
testicular development was established(63). 
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During the indifferent stage, the gonads are bipotential irrespective of their XX or XY karyotype. 
Gonadal differentiation into a testis or an ovary requires a delicate dosage balance in the timing 
and levels of expression of several genes(72). In most mammalian embryos, the transient 
expression of SRY , which maps to the Y chromosome, triggers a cascade of gene interactions 
ultimately leading to the formation of a testis from the indifferent gonadal ridge(73). SRY 
expression initiates in the middle of the gonad and expands toward the poles(74). The timing and 
level of SRY expression are critical for proper testis differentiation: delayed or decreased 
expression results in dysgenetic testicular or ovotesticular differentiation in the mouse (74,75). In 
most mammals, the SRY-box geneSOX9 is the earliest upregulated gene in the testis pathway 
downstream of SRY , followed by CITED4 and other members of the SOX family, including 
SOX3 , SOX10 and SOX13 , and many other genes that are critical for testicular 
differentiation(72,76,77). 
Genes involved in ovarian differentiation of the bipotential gonad increase their expression 
somewhat later. WNT4 and RSPO1 stabilize β-catenin, encoded by CTNNB1 , which promotes 
the expression of ovarian genes, such as FST (follistatin) and FOXL2 . The latter also counteracts 
SOX9 and other pathways involved in early testis development(72,78,79) 
 
 
2.2.2. Gonadal differentiation and growth in Ovotesticular DSD 
 
In Ovotesticular DSD, the normal regulation of gonadal differentiation is missing and the 
bipotentiality of the embryonic gonad persists, with the result that both ovarian and testicular 
tissues are formed. Gonadal differentiation may revert to a more primitive evolutionary level at 
which the rate of growth of the gonad determines its sexual direction. When this exceeds a 
certain threshold a testis may develop despite the absence of the TDF gene(80). 
In Ovotesticular DSD there are a number of different combinations of gonads e.g, ovary and 
testis, bilateral ovotestis, an ovotestis and contralateral ovary/testis. In patients who have two 
types of gonads present, they are distributed in a bilateral asymmetric fashion. The ovary is more 
commonly situated on the left side of the body, whereas the testis is more common on the right 
side of the body. One might, therefore, expect the ovotestes, being part ovary and part testis, to 
be distributed in a bilaterally symmetrical fashion, but this is not the case. The distribution of the 
ovotestes resembles that of the testes occurring predominantly on the right hand side. 
An ovotestis, therefore, represents a testicular gonad more often than an ovarian one and, 
like a testis, it is preferentially situated on the right side. 
The unequal distribution of ovaries and testes in Ovotesticular DSD cannot be easily explained 
genetically, as the TDF would be expected to be distributed evenly, and in equal quantities, in 
the cells of the body. If, however, gonadal differentiation is ultimately based on rates of growth, 
the question arises whether the asymmetry of gonadal growth in hermaphroditism can be related 
to an underlying asymmetry of the human body. By comparing growth characteristics in right 
and left gonads of normal human fetuses this possibility was tested(81). In the three variables 
investigated, i.e. weight, protein and DNA contents, the right gonads, on average, exceeded the 
left gonads. By combining the two sets of data, the relationship between growth and 
differentiation in human gonads can be deduced. 
Ovaries are smaller and do not grow as fast as testes; left gonads are smaller and grow 
17 
 
slower than right gonads. If there was any casual relationship between these phenomena, we 
would expect left gonads to have a tendency to become ovaries and right gonads to differentiate 
into testes. In normal development this relationship is of no consequence, since the sex 
chromosome constitution will override all other tendencies. 
However, in DSDs, we witness the breakdown of the sex chromosomal mechanism, and we also 
see the bilaterally asymmetrical development of ovaries and testes in accordance with the basic 
asymmetry of normal gonadal development(23). 
The significance of these results is the observed bilateral asymmetry of gonadal growth in human 
fetuses provides an explanation for the asymmetrical distribution of ovaries and testes in 
Ovotesticular DSD. 
When testicular tissue differentiates in an SRY –negative XX gonad, 2 different mechanisms can 
be envisaged: the increased expression of pro-testis genes or the insufficient expression of pro-
ovarian/anti-testis genes. 
An effort to make an accurate diagnosis is important for the provision of proper genetic 
counseling and long-term management. 
 
2.2.3 Mechanisms Underlying Testis Differentiation in SRY -Negative Individuals 
 
2.2.3.1 Increased Expression of Pro-Testis Genes 
SOX9 
The SOX (SRY-related HMG box) protein family includes a group of transcriptional regulators 
containing a highly conserved high-mobility-group domain(82). This domain was first identified 
in SRY. SOX9, mapping to 17q24.3 in the human, is expressed in several tissues including 
chondrocytes and testes but also in bile duct, the central nervous system, hair follicles, heart, 
lung, pancreas, and retina. In the XY mouse embryo, an increase in SOX9 expression is induced 
by SRY in the gonadal ridge. SOX9 then upregulates FGF9 and PGD2, and a positive feedback 
loop is established to further upregulate SOX9, which progressively becomes independent of 
SRY. SOX9 is responsible for Sertoli cell specification, thus initiating testis differentiation(83)  
and for triggering AMH production(84,85) SOX9 haploinsufficiency results in dysgenetic 46,XY 
DSD associated with campomelic dysplasia(6,86). Conversely, ectopic SOX9 expression in 
undifferentiated gonads of transgenic XX mice results in sex reversal with testis development 
and male phenotype, demonstrating that high SOX9 expression suffices to trigger testis 
differentiation in the absence of Sry (87).Adult gonads contain seminiferous tubules with Sertoli 
cells but no spermatogenesis, as expected in a male with2 X chromosomes. Similarly, XX dogs 
with an interstitial duplication of chromosome 9 which carry the SOX9 locus develop through the 
male pathway(88). Testicular and ovotesticular DSD in 46XX SRY –negative patients have been 
described in association with duplications study suggested that the extra dose of SOX9 is 
sufficient to initiate testis differentiation in the absence of SRY ; however, the gonadal histology 
was not described. A recent case of a boy with normal genitalia has also been reported with a 
SOX9 duplication(38). In line with the previous observation and with data in mice identifying 
relevant cis -activating elements within a SOX9 gonad-specific enhancer (89), duplications or 
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triplications of potential SOX9 regulatory sequences have subsequently been identified 
associated with XX maleness. In fact, a 178-kb duplication 600 kb upstream(90) and a 96-kb 
triplication 500 kb upstream(91) of the SOX9 coding sequence were initially identified as the 
cause of familial 46,XX testicular DSD in SRY -negative patients with small testes and 
azoospermia. Also, a 148-kb tandem duplication of the region –595 to –447 kb upstream of 
SOX9 was found in an SRY -negative 46XX patient with ovotesticular DSD, who presented with 
ambiguous genitalia. Two further cases with partially overlapping 17q24.3 duplications 500 kb 
upstream of SOX9 presented with dissimilar phenotypes: one was an infertile male with testes, 
while the other was an ovotesticular DSD with ambiguous genitalia (92). Finally, 3 recent reports  
have identified 7 further SRY -negative patients with 46,XX testicular or ovotesticular DSD, who 
carried duplications ranging from 68 to 83.8 kb, located 510–600 kb upstream of SOX9 , which 
overlapped with previously reported rearrangements and allowed refining the minimal region to 
a 40.7–41.9-kb element.(93–95) 
 
SOX3 
SOX3 is a single exon gene located in Xq27.1, which encodes a protein that is most similar to 
SRY and that is required for normal brain, pituitary and craniofacial development in mice and 
humans. The first infant with ambiguous genitalia and scrotal gonads, who carried a de novo 
mosaic 46,XX,dup(17)(q23.1q24.3) containing the SOX9 gene, as revealed by FISH, was 
reported in 1999 (96). The by mutations in humans and mice , its ectopic overexpression in the 
developing XX gonads provokes testicular development in a transgenic mouse model(97). 
Elegant experimental studies have shown that, just as SRY, SOX3 can act synergistically with 
SF1 to upregulate SOX9 expression and trigger Sertoli cell differentiation in the bipotential 
gonad(98). Concordantly, different rearrangements of the SOX3 locus have been associated with 
46XX testicular DSD, suggesting that overexpression of SOX3 can cause XX male sex reversal 
in humans. Duplications encompassing SOX3 have been reported in 5 SRY -negative 46,XX 
patients with male or ambiguous genitalia and functional evidence of the existence of testicular 
tissue(92,98,99), although no histological study of the gonads was reported in most of them. In 5 
other patients, the condition was associated with rearrangements involving the regulatory region 
of SOX3. A duplication of a common 206-kb region, located 566 kb upstream of the SOX3 
coding sequence, was found in four 46XX patients with testicular DSD(100), while a 773-kb 
duplication of chromosome 1 integrated 82 kb distal to SOX3 was described in a patient with 
testicular differentiation on one side and an ovary on the other side (101). We have recently 
reported the first case of an SRY -negative 46XX patient with ambiguous genitalia associated to a 
SOX3 duplication presenting with bilateral ovotestes(102). It should, however, be mentioned that 
a SOX3 duplication may not be sufficient to induce testicular differentiation when normal 
regulatory sequences are lacking in the duplicated DNA fragment (103). 
 
SOX10, a gene closely related to SOX9, maps to chromosome22q13.1 in humans and is involved 
in neural crest and glial development. As for SOX3 , a functional role for SOX10 has not been 
established in normal gonadal development(104), presumably because loss-of-function during 
gonadal development is likely to be masked by the action of other members of the SOX family. 
However, overexpression of Sox10 in the gonads of transgenic XX mice results in the 
development of testes and a male phenotype(105). Interestingly, complete or partial duplications 
of chromosome22 have been reported in a number of SRY -negative XX cases with ovarian 
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dysgenesis and/or testicular tissue differentiation(105). Relevant to the present review are a 
patient with masculinized external genitalia,dysgenetic testes and Mullerian remnants with a 
47,XX,+22 karyotype(106), a patient with ambiguous genitalia (ovotesticular DSD) associated to 
an inverted duplication of 22q13.122qter(107), and a patient showing only mild hypospadias and 




The DMRT gene cluster is located in human chromosome9p24.3 and comprises DMRT2 , 
DMRT3 andDMRT1 (109). DMRT genes have a conserved DNA-binding motif, the DM domain, 
and play critical roles in gonadal differentiation and gametogenesis. DMRT1 encodes a male-
specific transcription factor and has the most prominent role – amongst DMRT genes – in 
regulating testicular differentiation in all vertebrates. Distal 9p deletions encompassing the 
DMRT cluster are associated with dysgenetic and ovotesticular DSD in 46,XY patients(110). 
Although no SRY -negative 46,XX DSD patients with testicular tissue and DMRT1 
overexpression have as yet been identified, increased expression of Dmrt1 in the fetal gonads of 
transgenic XX mice is sufficient to drive testicular differentiation and male sex development 
(111). 
 
2.2.3.2 Insufficient Expression of Pro-Ovarian Genes 
WNT4 
 
WNT4 belongs to the WNT family, a large group of secreted glycoproteins encoded by 19 
distinct genes that are expressed in a tissue-specific fashion. WNT4 maps to 1p36.12, and there is 
clinical and experimental evidence of its role in sex differentiation. WNT4 cooperates with 
RSPO1, leading to a reduction in the phosphorylation and degradation of β-catenin. The 
consequent increase in β-catenin induces WNT-responsive genes and antagonizes 
SOX9(79,112). WNT4 upregulates DAX1 expression, which antagonizes SF1, and thereby 
inhibits steroidogenic enzymes. WNT4 overexpression has been associated to sex reversal in a 
XY patient(3) . Apart from its role in ovarian differentiation, WNT4 is also directly involved in 
Mullerian duct formation (79) and plays a critical role in the formation of the kidneys, adrenals, 
pituitary gland, and mammary tissue. The first experimental evidence of the role of WNT4 in sex 
development derives from the inactivation of the Wnt4 gene in mice (113). Wnt4 knockout XX 
mice are virilised, the Mullerian duct is absent, and the development of the Wolffian ducts 
resembles that of the male. The gonads are also masculinized, as revealed by the enhanced 
expression of the steroidogenic enzymes 3β-hydroxysteroid dehydrogenase and 17α-
hydroxylase, required for testosterone synthesis and normally suppressed in the fetal ovary. 
Heterozygous loss-of-function mutations of WNT4 have been described in three 46XX patients 
with mild virilization. The main complaint was primary amenorrhea due to Mullerian defects 
characteristic of the Mayer-Rokitansky-Kuster-Hauser syndrome and clinical signs of androgen 
excess(114), but no testicular tissue could be identified(115). Conversely, the inactivation of 
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both copies of WNT4 results in a severe clinical condition, known as the SERKAL syndrome, 
characterized by 46,XX DSD with ambiguous genitalia, renal agenesis, adrenal hypoplasia, and 
pulmonary and cardiac abnormalities. The presence of testicular DSD and ovotesticular DSD 
were reported in the same family(116). 
RSPO1 
RSPO1 is one of the 4 members of the R-spond in family, expressed during fetal development in 
the central nervous system, the limb buds and the body trunk, and the proximal posterior part of 
the anterior limb bud(117). The human RSPO1 gene is located in chromosome 1p34.3. As 
already mentioned, several lines of evidence have demonstrated that RSPO1 synergizes with 
WNT4 in XX gonads to stabilize β-catenin, thus acting as an activator of the canonical signaling 
pathway in ovarian development(79). In mice, the ovarian phenotype of the XX Rspo1 knockout 
is strikingly similar to that of Wnt4 knockout (117). Penetrance of the phenotype is slightly 
variable, and gonad morphology may range from dysgenetic gonads to ovotestes. Interestingly, 
β-catenin overexpression is able to rescue the abnormal masculinisation of the gonads of XX 
Rspo1 knockout mice, thus confirming that RSPO1 acts through the β-catenin signaling pathway. 
In humans, the first reported cases with loss-of-function mutations of the RSPO1 gene were 
associated with SRY -negative 46,XX DSD, palmoplantar hyperkeratosis and squamous cell 
carcinoma of the skin (19). The presence of ‘functional’ testes was assumed based on the 
absence of Mullerian derivatives and the masculinisation of the internal and external genitalia; 
however, no histological study of the gonads is reported. 
A second case with 46XXvirilisation associated with palmoplantar keratoderma, congenital 
bilateral corneal opacities, onychodystrophy, and hearing impairment was reported later. 
Laparoscopy showed an apparently normal uterus and left fallopian tube. Histology of the gonad 
biopsy showed the presence of ovotestis and a seminoma(118). Notably, the normal reproductive 




FOXL2 is a single exon gene encoding a forkhead/winged helix nuclear protein acting as a 
transcription factor, and mapping to 3q22.3 in humans. In most vertebrates, FOXL2 is one of the 
earliest markers of fetal differentiation of the ovary. In mice, Foxl2 does not seem essential for 
ovarian development in the XX fetus, but forced expression impairs testis differentiation in the 
XY fetus(119). FOXL2 continues to be expressed in the postnatal ovary, and ablation of FOXL2 
expression in the XX adult ovary results in its trans differentiation to testis(120) . In 46XX 
patients, loss-of-function of FOXL2 is associated with the blepharophimosis/ptosis/epicanthus 
inversus (BPES) 
syndrome with or without ovarian dysgenesis(121), but no development of testicular tissue or 





2.3. Models for mammalian sex determination 
The molecular mechanisms by which SRY triggers testis development are unknown. It 
is possible for SRY to act as either an activator or repressor of the transcription of target 
genes. Current knowledge is inconclusive and sometimes contradictory. Genetic models (based 
on either of the two possibilities) for mammalian sex determination have been proposed. 
 
2.3.1. The SOX model 
Since haploinsufficiency of SOX9 promotes ovarian rather than testicular differentiation, 
it has been proposed that inhibition of SOX9 in the genital ridge must therefore suppress testis 
formation and lead to a female phenotype. Because the presence of SRY promotes testis 
formation, a highly conserved gene, SOX3, has been suggested to provide the link between SRY 
and SOX9(122). 
Sox9 is expressed in the gonads of both XX and XYmice at 10.5dpc. At the onset of 
Sry expression, Sox9 is upregulated in XY embryos, and remains level or decreases in 
XX embryos. Sox3 is expressed at a low level in the gonad up to 11.5dpc, as is Sry. 
These patterns are compatible with competitive inhibition of Sox3 protein by Sry protein 
in binding to and regulating transcription of the Sox9 gene. In XX embryos, Sox S protein binds 
to and inhibits Sox Q transcription. In XY embryos, Sry protein would compete with Sox S 
binding and relieve this inhibition, permitting transcription of Sox9 and initiating testis 
differentiation (123). 
One of the more recent models proposed by (124) suggest that an autosomal testis repressor 
exists (the Z gene) that is active in females but that is itself repressed by SRY in males during 
sex determination. 
 
2.3.2. The Z gene model 
The Z gene model implies that a gene(s) other than SRY directly controls target genes 
in the male pathway, a view contradicted by the more usually accepted hypothesis that 
SRY directly activates a testis-determining cascade. This autosomal locus, Z, that confers male 
phenotypes when both copies of the recessive allele are present, even when SRY is absent, was 
the simplest way to interpret three pedigrees where the parents exhibited normal phenotypes, but 
in each family, two of the children were XX sex reversed males or 46,XX Ovotesticular 
DSDs(124). 
To explain the genetic observations - that SRY is not needed for male sex determination in the 
absence of Z - SRY has been proposed to antagonize or repress Z. In normal XX females, Z 
negatively regulates the expression of male specific genes. 
In normal XY males, SRY represses synthesis of Z or inhibits Z activity, thereby allowing 
expression of male specific genes, leading to testis development and a male phenotype. In XX 
patients who lack Z due to a mutation, inhibition of male specific genes does not occur, and, 
therefore, these XX individuals exhibit a male phenotype(124). XY individuals exhibiting a 
female phenotype can be explained in terms of a dominant mutation in Z, Z', which is insensitive 
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to SRY action. McEireavey et al proposed the existence of several ‘leaky’ Z mutants that 




2.3.3. The DSS-gene model 
Jimenez et al proposed that a single active copy of DSS (dosage- sensitive sex reversal) may 
function to silence male pathway genes (MPGs) in normal XX females, permitting the induction 
of the ovarian pathway (123).  This DSS gene model proposes that SRY inhibits the action of the 
copy of DSS present in XY individuals, thus permitting testis, differentiation. This implies that 
the Z and DSS genes may be identical, and that Z is not autosomal as originally proposed, but X-
linked as is DSS. A single copy of SRY, however, may be unable to counteract the effect of two 
active copies of DSS, so that male to female sex reversal would occur, as observed in humans 
with duplications of Xp21.  SF1 and WT1 induce the formation of the bipotential gonads in the 
embryos of either sex chromosome constitution. In XY individuals, SRYsuppresses the 
repression by DAX1 of SF1. As a result, SF1 is able to transactivate MPGs, including SOX9 and 
AMH (anti Mullerian Hormone). The resultant differentiation of the testes leads to inhibition of 
the female pathway genes (FPGs) and hormonal induction of the male phenotype. In XX 
individuals, the active copy of DAX1 represses SF1 and, therefore, this gene cannot activate the 
MPGs. Later in development, activation of FPGs leads to the development of ovaries and the 
consequent hormonal induction of the female phenotype. Functional oocytes may be necessary to 
inhibit MPGs, thus precluding transdifferentiation of the ovarian tissue into testicular tissue as a 
consequence of late activation of MPGs(125). 
Evidence for the involvement of autosomal and X-linked genes in several sex reversed 
syndromes in humans and other mammals suggests that the pathway is more complex 
than the models described above and involves genes that have functions other than sex 
determination. This complexity and pleiomorphism should not be surprising by analogy 
with the sex determination pathways of Drosophila melanogaster and Caenorhabditis 
elegans. Indeed, it would be surprising if mammalian sex determination were really as 




2.3. 4 A proposed cascade for sex determination 
A possible cascade of events, initiated by SRY, which results in testis formation has been 
proposed. Included in this cascade is SOX9, a hypothetical negative regulator of male 
development. Z and SF1 which binds to the MIS promoter and thus activates MIS.(124)The 
proposed sequence of events in a normal XY male, are as follows the expression of SRY triggers 
the cascade by activating a downstream gene, SOX9.SOX9, in turn, represses Z which (directly 
or indirectly) inhibits SF1 expression. In the absence of Z, SF1 expression is induced and hence 







2.4  A hypothesis on the molecular aetiology of Ovotesticular DSD 
 
2.4.1. The X chromosome inactivation theory 
 
In 1961, Mary Lyon postulated that dosage compensation for X-linked genes in mammals is 
accomplished by inactivating one of the two X chromosomes in females. 
X-inactivation occurs early in embryogenesis, at the 64 to 100 cell stage. It is thought to 
be a stochastic event; that is, each cell is equally likely to inactivate either the maternal 
or paternal chromosome. Neighboring cells do not influence the chromosome ‘choice’. 
Therefore, in normal females, approximately 50% of the cells transcribe genes on the 
maternal X chromosome (126). Some loci on the inactivate X chromosome are, however, 
transcribed. This late-replicating chromosome is relatively condensed during interphase and is 
visible as a Barr body at the nuclear membrane. 
The process of X-inactivation involves a regulatory gene, Xist (X-inactivation specific 
transcript). It is now known to represent the master switch locus regulating X inactivation. 
Xist maps to the X-inactivation centre (Xie) and is transcribed exclusively from the inactive X 
chromosome in female somatic cells and at the time of X-inactivation during spermatogenesis in 
the male (127). The RNA remains in the nucleus and coats the chromosome. X chromosome 
inactivation is a complex developmental process that is likely to involve a variety of molecular 
mechanisms. In addition to the mechanisms that initiate inactivation, other mechanisms act to 
maintain it with high fidelity during cell division. 
Although several models have been proposed to explain the mechanism of X inactivation at a 
molecular level, experimental evidence in support of these theories is lacking(128). 
An excellent candidate, however, for the mechanism that silences genes on the inactive 
X chromosome is DNA methylation. CpG islands on the active X are unmethylated 
whereas those on the inactive X are extensively methylated (128). 
 
Thus, it’s been proposed that testis formation can occur in an individual with a 46XX karyotype 
if a gene necessary for sex determination is mutated and is present and on the active X 
chromosome. The normal copy of the gene is found on the inactive methylated X chromosome 
and is therefore not expressed. This hypothesis is thus based on whether X chromosome 
inactivation in the testicular and ovarian tissue of the gonads is random or non-random in XX 
Ovotesticular DSDs. Non-random inactivation of either the maternal or paternal allele in either 
the testis or ovary would suggest that there is a gene(s) on the X chromosome which plays a role 
in testicular development in XX Ovotesticular DSDs. The basis of the X inactivation assay lies in 
the fact that one of the two X chromosomes in every female cell becomes inactivated in early 
fetal development. This is a random process that results in a mosaic pattern of X inactivation. 
The active and inactive X chromosomes may be distinguished from one another, in this case, on 
the basis of methylation. This X chromosome inactivation hypothesis can be assessed by 
examination of the methylation status of the CpG region near the polymorphic androgen 
receptor element (ARE) gene on the X chromosome. 
The method relies on methylation-sensitive restriction enzyme digestion and PCR. 
Methylated DNA sequences i.e., inactive X chromosomes, are selectively amplified 
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following digestion with HpaW. This assay is able to distinguish between the paternal and 
maternal alleles and to identify their methylation status. Thus it is possible to determine whether 














































                                                         CHAPTER THREE 
 
3.0 Materials and Methods 
3.1 Study Site 
The screening and of all study participants and drawing of their blood specimen were done at the 
Red Cross War Memorial Hospital in Cape –Town, South Africa. The blood specimen were then 
packaged appropriately and couriered by FedEx on the same day for whole genome sequencing 
by our partners at the Albert Einstein College of Medicine in New York, USA. 
3.2 Study Participants 
Participants enrolled into the study were patients who had histologically proven ovotesticular 
DSD and their biological parents. Blood specimens were also drawn from other healthy black 
individuals of the Bantu- speaking ethnicity to be used for controls. 
 
3.2. 1 Inclusion Criteria 
1. Patients with histologically proven ovotesticular DSD and their biological parents as 
study cases 
2. Healthy individuals from the Bantu speaking ethnic group who consented for their 
bloods to be taken as control 
 
3.2.2   Exclusion Criteria 
Patients diagnosed with DSD but without histologic confirmation of ovotestis or the presence of 
an ovary and testis. 
3.3 Study Design 
This was a prospective analytical study of patients with diagnosed with ovotesticular DSD at the 
Red Cross War Memorial Hospital and their biological parents. Hospital records were reviewed 
to select patients who had been diagnosed with ovotesticular DSD over the past 10 years 
(January 2007- December 2016). These were patients who had undergone gonadal biopsy as part 
of the work up for disorder of sexual differentiation and had histological evidence of 
seminiferous tubules and ovarian follicles present in both or either of their gonads. Their records 
were reviewed for data such as features of internal and external genitalia, hormonal assay results, 
histology of gonads and sex of rearing etc.  The parents of these patients were contacted on 
phone. Those who could be reached were informed of the study and if they agreed to partake in 
the study, they were scheduled to report to the Red Cross Hospital with the patient for informed 
consent and blood specimen to be taken. In the event where only one parent was available with 
26 
 
the patient, blood specimen were drawn from only the two of them or if both biological parents 
were not available, blood was drawn from the child alone. 
Blood specimens were drawn from each study participant into specimen tubes, labeled, tubes 
taped to prevent leakages and packaged for courier by FedEx to New York for genome 
sequencing. 
At the genetic pathology laboratory of the Albert Einstein College of Medicine, cell lines were 
created for each study participant and DNA isolated and quantified by Nanodrop technique. Then 
exome sequencing and functional studies were carried out. 
. 
3.4Sample/ Data Management: 
All samples were assigned a unique ID, consisting of a study identifier, family identifier, and 
sample identifier. This ID is used for all processes. A master file is kept by the research genetic 
counselor to match the study ID to the subject’s identifying information.  This file is password-
protected and stored on a secure server at Albert Einstein College of Medicine. 
 
All other study data were stored in a secure database on the server at Albert Einstein College of 
Medicine. 
 
High quality DNA was extracted from blood for all of subjects.  Lymphoblastoid cell lines were 
created for the selected cases. To create lymphoblastoid cell lines, white blood cells were 
separated from 10 ml of whole blood from each participant, using a ficoll-hypaque gradient and 
then transformed in culture by infection with Epstein-Barr virus to create a renewable source of 
DNA, RNA and actively dividing cells. 
 
3.4.1 Massively parallel sequencing. 
Following sample preparation using the Illumina library preparation kit, sequencing was 
accomplished using paired-end sequencing technology on an Illumina HiSeq2000 sequencer. 
Each sample was sequenced to between 30 and 35-fold coverage. Experience has suggested that 
this is an appropriate level of coverage for whole exome sequencing to capture most of the SNVs 
and small indels with high confidence. The data from the Illumina sequencers was analyzed first 
using the Illumina sequencing data analysis pipeline for quality control. For low sequencing error 
rates, this has been deemed to be sufficient for identifying low frequency variants. 
The following criteria are used to call SNPs and indels: 
1. Minimum root-mean-square mapping quality for SNPs = 25 
2. Minimum root-mean-square mapping quality for gaps =10 
3. Minimum read depth for SNV and indels = 3 
4. Maximum read depth for SNVs and indels = 256 
5. No more than 2 SNVs in a 10 base pair window 
6. No more than 1 gap in a 30 base pair window 
7. SNVs within 10 base pairs of an indel of quality 25 or higher will be filtered out. 
 
Paired end reads were aligned to the Human Reference Genome (NCBI Build 36) using the 
BWA software. Each alignment will be assigned a mapping quality score by BWA, which is the 
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Phredscaled probability that a read is misaligned. To call SNPs or indels, the Unified Genotyper 
of GATK was applied. Due to the fairly aggressive manner of the Unified Genotyper in making 
either SNP or Indel calls, the raw call sets were filtered to reduce false positive results based on 
Call Quality, Depth and Strand Bias etc. The basic functional annotation of SNPs/Indels was 
performed by ANNOVAR. The program determines whether the variants are located in exons, 
introns, ncRNA or intergenic regions and lists the related genes. If the variants are within exonic 
regions, the functional consequences of the variant are appended, including nonsynonymous 
single nucleotide variant, synonymous single nucleotide variant, frameshift insertion, frameshift 
deletion, nonframeshift insertion, nonframeshift deletion, frameshift block substitution, 
nonframeshift block substitution, stopgain and stoploss. For nonsynonymous DNA variants, the 
effect of the amino acid change will be predicted using BLOSUM62, SIFT, and Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/). 
 
For a known SNP from the 1000 Genomes Project32 or from dbSNP, the alternative allele 
frequency or heterozygosity, respectively, will be added to our annotation. At this stage we will 
have a series of annotations, each of which provides a measure of the likelihood that sequence 
changes are of functional significance. By scanning for their presence in the Human Gene 
Mutation Database at the University of Cardiff, Wales (http://www.hgmd.cf.ac.uk) or at the 
newly created MutaDatabase (http://www.mutadatabase.org), it was determined whether these 
variants had been described previously.  From studying 3 affecteds within a family, we expect 
that as few as 1-2 filtered variants and as many as 17 filtered variants may be shared among the 
affecteds. 
 
For de novo mutations, after correcting for sequencing errors and excluding SNPs or mutations 
of known frequency and significance, we may expected to have as few as 1-2 or as many as 5-10 
filtered variants. We anticipated that the causal mutations will be very rare in the population and 
not necessarily the same from case to case. Most may cluster in certain genes or pathways. For 
this reason, we looked for evidence of an excess of rare functional mutations in known 
developmental pathways, including those that have been implicated in prior linkage and genomic 
sequencing studies. 
 
To confirm the identity of the top 20 variants in each family and to perform linkage analysis, we 
performed TaqManq PCR genotyping assays on the affects and all other available members of 
the family. Thus, it was possible to determine which variants showed putative linkage to the 
phenotype (LOD score >1.0). In addition, for the sporadic cases, it was possible to demonstrate 
that the mutation is indeed denovo. This served as a basis for looking for functional effects. 
 
3.4.2 Functional effects of mutations. 
 
The expertise in the Ostrer laboratory and in the core facilities at Albert Einstein College of 
Medicine was tapped to use a toolkit of assays for rapidly screening missense, splicing and 
regulatory variants. These methods were also applied efficiently to studying small and large indel 
mutations. The first step was to assess the variant and determine whether it was likely to affect 
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RNA or protein abundance, splicing, targeting or interaction with co-factors. The choice of assay 
was based on the variant observed. Some of these analyses were performed for mutations known 
to cause DGDs, thus providing positive controls for these experiments. These assays were 
applied to lymphoblastoid cell lines that were derived from patients. Mutant and wild-type cell 
lines from patients were used to assess the effects of mutations on transcripts and proteins, if the 
repertoire of genes is expressed in this cell type. 
qPCR experiments were designed and performed to test effects of variants on RNA abundance 
using ABI Taqman expression probes. The experiments were designed not only to test the 
abundance of the various human isoforms of these transcripts, but also to test for aberrant 
splicing. If alternative splicing was suspected, then the qPCR products were cloned and 
sequenced to identify the effects of the aberrant splicing. 
 
Proteins were quantified and analyzed for protein-protein interactions by Western blot analysis 
using infrared fluorescence reporting secondary antibodies that generates signals for different 
epitopes. For example, these imaging systems quantify the phosphorylated and the non-
phosphorylated forms of proteins and the internal loading standard, such as histone, α-tubulin or 
β-actin. Multiple proteins can be analyzed simultaneously by the use of primary antibodies from 
different species, which increase the accuracy of quantification and comparison. Moreover, we 
have shown that the efficiency of these methods can be enhanced by performing FCM-Western 
analysis. Processing with secondary antibodies occurred according to manufacturer’s protocol 
and selection of primary antibodies. Sufficient biological replicates were performed to achieve 
statistical analysis and graphical representation. The intensities for each protein was normalized 
to the suitable loading controls and results presented as box plots of mean and standard 
deviation, and then compared between groups by Student’s t-test. Significant results were 
confirmed by conventional Western blot analysis. As with the RNA analysis, statistically 
significant increases or decreases in variant versus wild-type was taken as indication of a positive 
result. Notably, FCM-Western analysis was performed in a 96 or 384-well format, allowing for 
testing of multiple replicates and multiple different epitopes simultaneously, thus markedly 
enhancing the throughput. 
 
Binding partners for co-immunoprecipitation experiments were chosen from published reports 
and pathway analysis and selected on the basis of interacting with domains in which a variant 
amino acid residue had been identified. Suitably reactive antibodies were selected from 
published reports and the Albert Einstein College of Medicine Analytical Imaging Core. An 
antibody for the protein of interest was incubated with a cell extract in a non-denaturing buffer in 
the presence of protease and phosphatase inhibitors, so that the bait antibody will bind the 
protein along with its complex in solution. 
 
The lysate was pre-cleared by binding to a non-specific antibody and the antibody/antigen 
complex  pulled out of the sample using protein A or G-coupled magnetic Dynabeads, which 
physically isolates the protein of interest from the rest of the sample. Protein G-coupled 
Dynabeads was used for monoclonal antibodies and protein A-coupled beads for polyclonal 
antibodies. The sample was then bound to antibody-conjugated beads for Western analysis, using 




Population prevalence. To determine the prevalence of these mutations in the ethnic population 
for each of these families, 200 samples previously collected under anonymized specimen study 
protocols were genotyped from the corresponding group – Hispanic/Latino, Dominican, 
Ashkenazi Jewish, African American and European. These genotyping assays were created with 
suitable positive and negative controls. Should they have significance for the health of the 
population involved, approval will be sought from the New York State Department of Health for 








3.5 Data Analysis 
 
Gene analysis was done for mutations in the genome of patients (probands) and their mothers. 
 
1. Dominant gain in function mutation: 
 
Prediction: One variant found in all probands and in no mothers.  The genes looked for were the 
testis promoting genes. 
Gene list: SRY, RAC1, MAP3K4, AXIN1, SOX3, SOX8, SOX9, FGF9, FGFR2, SRY, 
GADD45Y 
Examples of predictions: 





2. Haploinsufficiency (Dominant) 
 
Prediction: One variant found in all probands and in no mothers. The genes looked for were the 
genes which cause down regulation of testis development. 
Gene List: RHOA, ROK, ERK1, ERK2, FRAT1, P38 
Examples of predictions: 




1. Dominant (Other) 
 
Prediction: One variant found in all probands and in no mothers. All genes related to DSD were 



















Examples of predictions: 






Triage filters ( Cartagania) 
 
• Population Frequency 
– <5% frequency in any of the following: 
• ESP6500 
• ExAC 
• 1000 Genomes Phase 1 
• 1000 Genomes Phase 3 
• dbSNP 
• Coding Effect 
– Excluding Synonymous mutations 
• Genes/Regions 
– Gene List (Total DSD) 
– Cohort 
– Keep variants that are present in all probands as: 
• Heterozygous wt / var x 
• Heterozygous var x / var y 
• Hemizygous (?) 
• Homozygous var x / var  x (UPD?) 
– Exclude variants that are present in all mothers as: 
• Heterozygous wt / var 
• Heterozygous var x / var y 
• Hemizygous (?) 




Fig 3.1 Diagram of analysis for mutant dominant gene 
1. Recessive
Prediction: Variant found on both alleles in probands and only on one allele in mothers. 
Examples of predictions: 
(varX is pathogenic) 
Triage filters (Cartagenia) 
• Population Frequency












• 1000 Genomes Phase 1
• 1000 Genomes Phase 3
• dbSNP
• Coding Effect
– Excluding Synonymous mutations
• Genes/Regions
– Gene List (Total DSD)
– Cohort
– Keep variants that are present in all probands as:
• Homozygous var x/ var x
• Hemizygous (?)
– Exclude variants that are present in all mothers as:
• Homozygous var x/ var x
• Hemizygous (?)
Fig 3.2 Diagram of analysis for mutant recessive gene 
35 
3.6 Ethical and legal considerations 
Ethical clearance for the study was obtained from the Human Research Ethics Committee 
(HREC) of the University of Cape Town (UCT). Permission was initially obtained from the 
Departmental Research Committee of the Red Cross Hospital.  The Departmental Research 
Committee of the Red Cross Hospital is the office that coordinates, registers and supervises all 
research works that take place in the hospital.   This office was first notified of the study with an 
application letter and the research proposal. Registration of the research and permission for it to 
be conducted in the hospital was granted after the research proposal was approved. Then the 
HREC of the UCT and Ethics was contacted for ethical clearance which it granted after studying 
the research protocol and ensuring that the highest ethical standards were to be maintained in 
conducting the study.  
A written informed consent (Appendix I) was obtained from all study participants after a general 
description of the study and the essence of their participation was verbally explained to them in a 
language they understood. Informed consent for patients who were less than 18years was 
obtained from their parents or guardians although the patient himself was also informed for his 
permission if he/she was old enough to understand. Patients were assured that participation was 
voluntary and that refusal to participate in the study was not going to affect management. Once 
the study genetic results were ready, a genetic counselor will link results back to the family and 
individual participants for appropriate genetic counseling. Patients were also assured of 
confidentiality in the handling of the data to be obtained from them. Information obtained from 
the study participants and the results of gene sequencing was used for no other purpose other 
than the study and only the researchers have access to it. It shall be retained for at least 5years 




The retrospective review of 30 patients’ files, revealed 15 patients with ovotesticular DSD. 
Seven (7) of these patients and their biological parents consented and had blood specimen taken 
for whole gene analysis. 
Clinical Findings 
Thirteen of these 15 patients have a 46XX karyotype while the karyotype of 2 patients was 
unknown. The sex of rearing for the 15 ovotesticular DSD patients is 40% male and 60% female 
as shown in figure 1. As shown in figure 2, 53% of patients presented with hypospadias while 
7% did not have hypospadias (the presence or absence of hypospadias was not recorded for 40% 
of patients). Furthermore, 33.3% of the patients had palpable gonads (5 out of 15), with 40% (2 
out of 5) being on the right and 60% (3 out of 5) being on the left. No patient had bilateral 
palpable gonads. 53.3% of patients did not have a palpable gonad. 
Histologic Findings 
All 15 patients had undergone a gonadal biopsy at Red Cross War Memorial Children’s hospital 
to confirm the diagnosis. This biopsy found ovotestes to be the most common gonad, accounting 
for 63.3% of gonads. Ovaries accounted for 26.7% of gonads while testes accounted for 10% of 
gonads. 
Gonadal Laterality and Distribution 
Furthermore, 14 out of 19 ovotestes (73.7%) were found on the right side of the patient’s body 
while 7 out of 8 ovaries were found on the left side of the patient’s body. Four patients (26.7%) 
presented with bilateral ovotestes. Bilateral ovotestis indicates that ovotestes were found on the 
left and right ie. 8 ovotestes were present and 4 sets of bilateral ovotestes were seen. Eight 
patients (53.3%) had an ovotestis and ovary with 7 of those patients presenting with the ovary on 
the left (46.7%). Three patients (20%) had an ovotestis and testis with all 3 patients presenting 
with the testis on the right. No patient presented with an ovary on one side and a testis on the 
other. 
Laparoscopic Findings 
At laparoscopy, it was found that 10 out of 15 (66.7%) patients had a uterus, with 5 out of 10 
(50%) presenting with an abnormal uterus and the remaining 50% with a normal uterus. It was 
also found that 7 out of 15 patients had one or both fallopian tubes. Five out of 7 (71.4%) 
patients presented with normal fallopian tubes while the remaining 2 patients (28.6%) had 
37 
abnormal fallopian tubes. There was no comment on the presence or absence of fallopian tubes 











Table 4.1.        Table to show the type of gonad found. 
Gonad Number of gonads (%) 
Ovotestis 19 63.3 
Ovary 8 26.7 
Testis 3 10 







Figure 4.2.              
Hypospadias 


































.  Table 4.2    Laterality of gonads in percentages. 
Gonad Number on right (%) Number on left (%) 
Ovotestis 14 (46.7%) 5 (16.7%) 
Ovary 1 (3.3%) 7 (23.3%) 
Testis 0 3 (10%) 
Total 15 (50%) 15 (50%) 
 






Left gonad Right gonad 




Ovotestis Ovotestis 4 26.7 
Ovotestis Ovary 1 6.7 
Ovary Ovotestis 7 46.7 
Ovotestis Testis 3 20 
Testis Ovotestis 0 0 
Testis Ovary 0 0 
Ovary Testis 0 0 















Right Left Bilateral Right Left Right Left 















































Figure 4.5           Laparoscopic presentation of uterus 
and fallopian tubes 
Present Present Absent No comment 
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B. Summary of results of whole genome sequencing. 
 
Seven (7) patients with histological confirmation of Ovotesticular DSD and their biological 
parents consented to have blood specimen taken for whole-gene analysis. 
 
Gene analysis was done for mutations in the genome of patients (probands) and their mothers. 
 
2. Dominant gain in function mutation: 
 
Prediction: One variant found in all probands and in no mothers.  The genes looked for were the 
testis promoting genes. 
Gene list: SRY, RAC1, MAP3K4, AXIN1, SOX3, SOX8, SOX9, FGF9, FGFR2, SRY,GAD 
D45Y 
The results did not find a mutation in any of these genes present in all probands. 
 
3. Haploinsufficiency (Dominant) 
 
Prediction: One variant found in all probands and in no mothers. The genes looked for were the 
genes which cause down regulation of testis development. 
Gene List: RHOA, ROK, ERK1, ERK2, FRAT1, P38 
The results did not find a mutation in any of these genes present in all probands. 
 
4. Dominant (Other) 
 
Prediction: One variant found in all probands and in no mothers. All genes related to DSD were 





Table 4.4 List of Genes studied 
The results did not find a mutation in any of these genes present in all probands. 
5. Recessive
Prediction: Variant found on both alleles in probands and only on one allele in mothers. 
All genes were analyzed but the results did not find any convincing causal variant for 
Ovotesticular DSD. 
CBX2 DVL WNT7B BMP15
DHH GATA4 WNT8A NR0B1
SOX9 SOX10 WNT8B NR0B2
FGF9 AXIN2 DVL1 NR5A1
FGR2 ERK1 DVL2 SOX3
SF1 ERK2 DVL3 SRY
MAP3K4 RSPO2 WNT8D WT1
GSK3B RSPO3 WNT9A CDKN1C
AXIN1 RSPO4 WNT9B GSK3B
DAX1 LGR4 WNT10-A MAPK14
RAC1 LGR5 WNT1-B SPRY2
FLNB LGR6 WNT11 ROCK1
ROCK WNT1 WNT16 CYP21A2
RHOA WNT2 SFRP1 HSD3B2
DMRT1 WNT3 SFRP2 CYP11B1
MAP3K1 WNT4 FRZB POR
FRAT1 WNT5A SFRP4 CYP17A1
WNT4 WNT5B SFRP5 STAR
RSPO1 WNT6 CTNNB1 CYP19A1










The primary objective of this study was to determine the genetic basis of 46XX Ovotesticular 
DSD among black South Africans. Whole genome analysis was performed on patients with 
46XX Ovotesticular DSD and their biological parents to identify possible variants that may be 
responsible for the high prevalence of 46XX Ovotesticular DSD in this population. The clinical 
features of these patients were also analyzed as part of the study.  Generally, the clinical features 
of the patients in this study was found to be consistent with those found in previous studies on 
black South Africans with Ovotesticular DSD and the clinical presentation again varied 
significantly with those found in patients from other parts of the world.  Thus, this study also 
showed the uniqueness of Ovotesticular DSD among black South Africans 
 
5.1:  Karyotype 
 
This study found that the most common karyotype for Ovotesticular DSD in South Africa is 
46XX. 13 of the 15 patients (86.7%) reviewed were 46XX. The genotype of the remaining 2 
patients was not documented. This is consistent with findings from other parts of South African.  
In 2008, Wiersma and Ramdial(33) found that 88% of patients with Ovotesticular DSD have a 
46XX karyotype with the remaining patients having either a 46XY karyotype, a chimeric 
46XX/46XY karyotype or a 46XX/XO mosaic pattern.
2 
However, when compared to other 
countries, the karyotype of patients with ovotesticular DSD shows geographical variations. In 
Europe 40.5% of 74 cases were 46,XX karyotype and 21.0% of the patients in North America 
had chromosomal mosaicism(30).Krob et al also observed that the 46,XY karyotype is extremely 
rare (7%) and equally distributed through Asia, Europe and North America(30). The relatively 
high prevalence of 46XX karyotype in South African as compared to other parts of the world 
probably suggests a different cause of Ovotesticular DSD in South Africa. 
 
5.2:  Type of Gonad 
This study found that the ovotestis is the most common, accounting for 63.3% of gonads in 
Ovotesticular DSD patients. This was followed by the ovary, which accounted for 26.7% and 
lastly, the testis, which accounted for 10%. Similarly, other South African studies concluded that 
the ovotestis accounts for more than 50% of the gonads in ovotesticular DSD patients. Ramsey et 
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al  conducted a study in 1988 and found that ovotestes were found in 52.8% of patients while 
Wiesman and Ramdial found  in 2008  that ovotestes were found in 54% of South Africans with 
ovotesticular DSD(22,33). Krob et al also found the most common gonad in patients with 
Ovotesticular DSD worldwide was the ovotestis, present in 44.4% of 568 gonads (30). Gonads 
with testicular tissue were more frequent on the right side of the body, while pure ovarian tissue 
was more common on the left both in South Africa and also in other parts of the world. 
(33,22,30).It is interesting to note that South African patients do not only have relatively higher 
percentages of ovotesticular DSD but as compared with other parts of the world where most of 
these ovotestis have a bipolar constitution, the most common constitution of ovotestis in South 
Africa is the admixed type as found by Weismar and Ramdial(33). This is also another 
observation that suggests the possibility of a different aetiology for Ovotesticular DSD in South 




5.3 Distribution of gonad 
The most common distribution is unilateral, with an ovary and ovotestes being present. This 
accounted for 53.3% of patients (8 out of 15 patients) with the majority of patients having an 
ovary on the left and an ovotestis on the right (7 out of 8 patients ie. 87.5%). This finding was 
consistent with the observation by Ramsay et al in their study which showed that in South Africa 
51.4% of patients present with this unilateral distribution of gonads. Additionally, these studies 
found that the ovary was also most commonly found in the left pelvis(22). Vilain also stated that 
the distribution worldwide is 34% ovotestes/ovary, 29% ovotestes/ovotestes and 25% 
ovary/testes(32). 
In this study, bilateral ovotestes are the second most common distribution, accounting for 26.7% 
of gonadal distributions. This is consistent with the observation by Vilian. Similarly, Ramsay and 
colleagues found that bilateral ovotestes was the second most common gonadal distribution in 
South Africa, accounting for 18.9% of gonadal distribution in their study (22)
. 
Therefore, gonadal distribution in South Africa is generally consistent with that from other parts 
of the world. 
 
5.4 Sex of Rearing 
This study found that, in South Africa, patients with ovotesticular DSD were more 
commonly raised as female than males. 60% of the patients were raised as females while 
40% of the patients were raised as males. This is consistent with the study by Ramsay et 
al, based in South Africa, which found 17 out of 33 patients (51.5%) to be female and 13 
out of 33 patients (39.4%) to be male (3 patients’ sex was ambivalent)(22).This shows a 
change in trend when compared with the observation by Van Niekerk in 1974 which 
showed that in the past, most of these patients were raised as males.(20). This change 
may have been an influence of the degree of virilization and the fact that that normal 
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ovarian tissue could be preserved in those being raised females. Hence, since the ovary is 
the second commonest gonad found in these children it is likely contributing significantly 
to the reversed trend for the chosen sex of rearing. The sex of rearing in South Africa 
now shows a different trend to that from other parts of the world where two thirds of 
patients are reared as males(39). This also shows that Ovotesticular DSD in South Africa 
presents with features which are different from those observed worldwide and thus may 
suggest a possible difference in etiological factors. 
  5.5: Findings at laparoscopy 
This study also explored the presence and presentation of a uterus and fallopian tubes in 
patients with ovotesticular DSD. The majority of patients, (66.7%) presented with a 
uterus, 50% of which were abnormal or rudimentary while the remaining 50% were 
normal uterus. Furthermore, 46.7% of patients presented with fallopian tubes, the 
majority of which were normal in structure. This is consistent with findings that a uterus 
is usually (90%) present based on cases reported worldwide and as in Van Niekerk’s 
sample(20). Sometimes the uterus is bicornuate or unicornuate. Similarly, in their series, 
also from South Africa, Wiersma and Randial reported that 58% of 125 patients had a 
“uterine structure”(33).The absence of a uterine horn often indicates ipsilateral testis or 
ovotestis. The fimbriated end of the fallopian tube is usually occluded ipsilateral to an 
ovotestis. The presence or absence of fallopian tubes or Wolffian derivatives reflects the 
ipsilateral gonad. A fallopian tube is invariably present ipsilateral to an ovary, whiles a 
vas deferens, epididymis, and, often, a seminal vesicle are usually present ipsilateral to a 
testis. A fallopian tube or Wolffian derivatives may be present on the side of an ovotestis, 
although most often a fallopian tube is present. Although fallopian tubes and Wolffian 
derivatives are usually not both present on the same side, even on the side of an ovotestis, 
this combination has been observed occasionally(36). 
5.6 Genetic analysis for the etiology of 46XX Ovotesticular DSD. 
Whole genome analysis was performed on patients with 46XX Ovotesticular DSD and their 
biological parents to identify possible variants that may be responsible for the high prevalence of 
46XX Ovotesticular DSD in black South Africans. The study looked out for a variant in any of 
the genes known to promote formation of the testis. It was hypothesized that if a variant was 
found in any of these genes for all probands, then it will be the likely genetic aetiology for the 
formation of a testis in these 46XX individuals. The genes considered in this category were the 
SRY, RAC1, MAP3K4, AXIN1, SOX3, SOX8, SOX9, FGF9, FGFR2, SRY and GADD45Y 
genes. Although most of these genes especially duplications and triplications of SOX9 have been 
found in patients with 46XX sex reversal and some patients with 46XX Ovotesticular DSD from 
other parts of the world , none of these genes was found as a causal variant in any of  the 
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probands. This is consistent with the findings of Padoa who also found no convincing role of 
SOX9 in the etiology of 46XX Ovotesticular DSD in South Africa.(129) 
 
The study did not find any convincing evidence for haploinsufficiency of the genes RHOA, 
ROK, ERK1, ERK2, FRAT1, P38 which are known to cause down regulation of testes 
development. There was no convincing evidence of the role of genes known to cause DSD as the 
possible cause of 46XX Ovotesticular DSD in the patients for this study. This is consistent with 
similar studies for the molecular etiology of 46XX Ovotesticular DSD among South Africans 
which has so far been elusive (129). 
This study has been consistent with other studies which show that Ovotesticular DSD in South 
Africa has different clinical presentation compared with those from other parts of the world. 
Almost all patients with Ovotesticular DSD in South Africa are 46XX and almost all the 
ovotestis are admixed with the majority of patients being raised as females. It is therefore not 
surprising that whereas genetic mutations such as duplication and triplication of SOX 9 has been 
found in patients with XX Ovotesticular DSD from other parts of the world, this study and 
similar South African studies have still not found any convincing genetic variant for this 
condition among South Africans.  
 
It is possible that the unique features of 46XX Ovotesticular DSD among South Africans truly 
imply an alternate etiology in comparism to patients from other parts of the world. Although the 
full sequence of these genes was examined in this study, it is possible that there is a common 
etiologic factor in some aspect of the genome which has not been critically examined yet. 
 
 
Limitation of the Study: 
 
This study is limited by the small number of study participants. This is due to the rarity of 
Ovotesticular DSD and the refusal of some patients diagnosed with this disorder to consent to the 












The gene(s) involved in the etiology of XX Ovotesticular DSD have not yet been 
identified. A previous study on South African XX Ovotesticular DSD failed to 
implicate major environmental factors in the disorder(22). A simple single-gene explanation is 
unlikely if one considers that most cases are sporadic. (22,64) 
 
Although others have found gene mutations such as duplication of SOX 9 in patients with 
Ovotesticular DSD from other parts of the world, this study and similar studies from South 
Africa have failed to demonstrate any gene mutations in Ovotesticular DSD in South Africa. 
However, this study has once again confirmed the strikingly higher frequency of 46XX 
Ovotesticular DSD in South Africa, the different pattern of gonadal distribution and the high 
frequency of female sex rearing as compared to other parts of the world. These unique 
differences suggest a possible different etiology to Ovotesticular DSD in South Africa. 
Although the full sequence of these genes was examined in this study, it is possible that there is a 
common etiologic factor in some aspect of the genome which has not been critically examined 
yet. 
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